ImmuCell (ICCC) and Akers Biosciences (AKER) Critical Survey

ImmuCell (NASDAQ:ICCC) and Akers Biosciences (NASDAQ:AKER) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Insider & Institutional Ownership

14.0% of ImmuCell shares are held by institutional investors. Comparatively, 50.7% of Akers Biosciences shares are held by institutional investors. 17.7% of ImmuCell shares are held by company insiders. Comparatively, 8.9% of Akers Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares ImmuCell and Akers Biosciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmuCell $10.43 million 3.76 -$160,000.00 N/A N/A
Akers Biosciences $3.93 million 4.38 -$7.36 million N/A N/A

ImmuCell has higher revenue and earnings than Akers Biosciences.

Volatility & Risk

ImmuCell has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Akers Biosciences has a beta of -0.93, indicating that its share price is 193% less volatile than the S&P 500.

Profitability

This table compares ImmuCell and Akers Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ImmuCell -13.09% -3.89% -2.69%
Akers Biosciences -346.69% -107.79% -85.96%

Analyst Recommendations

This is a summary of current recommendations for ImmuCell and Akers Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmuCell 0 0 0 0 N/A
Akers Biosciences 0 0 0 0 N/A

Summary

ImmuCell beats Akers Biosciences on 7 of the 9 factors compared between the two stocks.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves. It also provides California Mastitis Test, which is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing purified Nisin treatment for subclinical mastitis in lactating dairy cows; and selling various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to animal health distributors, fleet stores, and direct to farms. The company was founded in 1982 and is headquartered in Portland, Maine.

About Akers Biosciences

Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ‘Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth ‘Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply